Benign Conditions

Benign Prostatic Hyperplasia

Bladder Cancer

Female Urology

Genitourinary Cancers

Genomic Testing

Hormone Therapy

Kidney Cancer

Challenging Anatomy

Innovative Techniques

Laser Lithotripsy

PCNL Tech & Devices

Ureteroscopy Tech & Devices

Kidney Stones

Men's Health

Next-Generation Imaging

Voiding Dysfunction

OAB and Incontinence

Pediatrics

Controveries in Urologic Cancer

Drug Therapy

Prostate Cancer

Sexual Dysfunction

UTUC

Cosmetic Surgery

Urologic Surgery

Business

Practice Management

Malpractice Consult

Health Law & Policy

Media

Case-Based Peer Perspectives

Investigator Perspectives 

Medical World News

Podcasts

Urology Medical Perspectives

UTv Videos

Peer Exchange

News Network

Virtual Tumor Board

Insights

Medcast

Peers & Perspectives

Conferences

Conference Listing

Conference Previews 

Conference Recaps

Publications

Urology Times Journal

Editorial Advisory Board

Urologists in Cancer Care

Supplements and Featured Publications

CME/CE

Resources

Begin Your Journey: Tackling Burnout

Live Events

Interactive Tools

Job Board

Partners

Subscribe

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do not sell my Personnal Information

Urology Times | News & Insights for Urologists & Health Professionals

Facebook

LinkedIn

Spotlight

Peers and Perspectives

Clinical

1rem

View

Enhanced Detection in Prostate Cancer: The Promise of 64Cu-SAR-bisPSMA for Improved Imaging and Recurrence Reduction

The CLARIFY Trial Design and Objectives for PSMA Imaging

Videos

Michael Gorin, MD explores the PSMA imaging landscape, emerging agents with extended imaging windows, key copper-based imaging trials, and the anticipated impact of next-day imaging pending CLARIFY trial results.

A medical expert discusses how advancements in PSMA PET imaging, including the development of agents like 64Cu-SAR-bisPSMA, address current challenges in sensitivity and logistical issues, potentially enhancing tumor detection and patient outcomes.

PSMA PET Imaging: The Landscape and Current Challenges

A medical expert discusses how emerging copper-based developments in PSMA imaging, particularly the 64Cu-SAR-bisPSMA agent, offer advancements in tumor detection and imaging logistics compared to traditional agents.

Emerging Copper-Based Developments in PSMA Imaging 

Michael Gorin, MD provides the background and results of two key imaging trials that reviewed the efficacy of this new copper-based agent. 

COBRA AND PROPELLER: Background and Results of Prior PSMA Imaging Trials

Michael Gorin, MD discusses the impact of next-day imaging and the potential imaging improvements as physicians await the results of the CLARIFY trial. 

Potential Impact of Forthcoming CLARIFY Trial Results 

The CLARIFY Trial Design and Objectives for PSMA Imaging

EP: 1.PSMA PET Imaging: The Landscape and Current Challenges

EP: 2.Emerging Copper-Based Developments in PSMA Imaging

EP: 3.COBRA AND PROPELLER: Background and Results of Prior PSMA Imaging Trials

EP: 4.The CLARIFY Trial Design and Objectives for PSMA Imaging

EP: 5.Potential Impact of Forthcoming CLARIFY Trial Results